A recent analysis reveals that individuals who are overweight or obese and discontinue their weight-loss medications experience quicker weight regain compared to those who halt a diet or exercise regimen. Weight loss drugs that contain semaglutide, found in popular medications like Ozempic and Wegovy, have gained significant traction. However, nearly half of obese individuals using these drugs, known as glucagon-like peptide agonists or GLP-1s, discontinue usage within a year due to high costs and gastrointestinal side effects.
Researchers emphasize the importance of understanding weight regain due to the associated risks of diabetes and heart disease. To explore this further, a review led by Sam West, a postdoctoral researcher at the University of Oxford, and his team examined data from randomized trials and observational studies involving over 6,000 overweight or obese adults on GLP-1s or older weight-loss medications, compared to 3,000 participants in behavioral weight management programs.
After ceasing treatment, individuals on weight-loss medications regained an average of 0.4 kg per month, resulting in an average regain of 4.8 kilograms or 10 pounds in the first year. The study suggests that markers for diabetes and heart disease, such as high cholesterol and blood pressure levels, would return to pre-treatment levels in less than two years.
The rapid weight regain after discontinuing medication surprised researchers, with individuals regaining weight nearly four times faster than those who stopped exercising or adhering to their diets. The study encompassed various diet plans, including group programs like Weight Watchers and meal replacements. Even individuals who discontinued behavioral programs experienced weight regain.
In terms of Canadians, Dr. Sonja Reichert, an associate professor at Western University specializing in obesity and diabetes, highlights that new weight loss medications are not a quick solution for obesity. Reichert emphasizes the long-term nature of these medications, comparing them to treatments for chronic conditions like high blood pressure.
The challenges of managing excess weight and the impacts of medications are exemplified by Heather White, a 76-year-old from Toronto who discontinued Ozempic due to side effects after seven months. After focusing on dietary choices without medication for two years, White eventually started a new weight-loss medication, Mounjaro, with positive outcomes.
Addressing the issue of weight regain, experts point out that while GLP-1 medications offer benefits, they do not have lasting effects. Strategies to maintain weight loss and alter the food environment are crucial to sustaining long-term weight management. Support during treatment, such as nutritional guidance, has been shown to enhance weight loss outcomes.
The reasons behind the accelerated weight regain post-medication cessation remain unclear and require further research. Experts emphasize the importance of coping skills to manage hunger effectively during weight loss and after discontinuing medications. Efforts to improve access to medications, reduce costs, and offer comprehensive behavioral programs are seen as promising advancements in the field to support healthy lifestyle changes.